28948-58-5

Basic information

• Product Name: 7-CHLORO-THIENO[2,3-C] PYRIDINE
• Synonyms: 7-CHLORO-THIENO[2,3-C] PYRIDINE;7-Chlorothieno[2,3-c]pyri...;Thieno[2,3-c]pyridine, 7-chloro-
• CAS NO: 28948-58-5
• Molecular Formula: C₇H₄ClNS
• Molecular Weight: 169.63
• Product Categories: API intermediates;Heterocycle-Pyridine series
• Mol File: 28948-58-5.mol

Chemical Properties

• Boiling Point: 296.5 °C at 760 mmHg
• Flash Point: 133.1 °C
• Appearance: /
• Density: 1.435
• Vapor Pressure: 0.00253mmHg at 25°C
• Refractive Index: 1.695
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.35±0.30(Predicted)
• CAS DataBase Reference: 7-CHLORO-THIENO[2,3-C] PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-CHLORO-THIENO[2,3-C] PYRIDINE(28948-58-5)
• EPA Substance Registry System: 7-CHLORO-THIENO[2,3-C] PYRIDINE(28948-58-5)

Safety Data

• Hazardous Substances Data: 28948-58-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Chloro-thieno[2,3-c]pyridine is utilized as a key intermediate in the synthesis of various pharmaceuticals due to its unique chemical structure and reactivity. Its incorporation into drug molecules can enhance their therapeutic effects and target specific biological pathways.
Used in Agrochemical Industry:
In the agrochemical sector, 7-Chloro-thieno[2,3-c]pyridine serves as a crucial component in the development of new agrochemicals. Its properties allow for the creation of compounds that can effectively address pest control and crop protection needs.
Used in Research and Drug Discovery:
7-Chloro-thieno[2,3-c]pyridine is employed as a research tool in the study of protein kinase C inhibition. Its potential as an inhibitor makes it valuable for investigating the role of this enzyme in various diseases and for identifying new therapeutic targets.
Used in Medicinal Chemistry:
7-CHLORO-THIENO[2,3-C] PYRIDINE has demonstrated promising activity in the treatment of a range of diseases and disorders. As such, it is used in medicinal chemistry to explore its therapeutic potential and to develop new drugs that can benefit from its unique properties.

InChI:InChI=1/C7H4ClNS/c8-7-6-5(1-3-9-7)2-4-10-6/h1-4H

Upstream product

• 738544-01-9 thieno<2,3-c>pyridine 6-oxide 
• 28424-61-5 (2E)-3-(2-thiophenyl)-2-propenoyl chloride 
• 1124-65-8 3-(2-thienyl)-2-propenoic acid 
• 104587-43-1 thieno<2,3-c>pyridine 6-oxide hydrochloride 
• 28981-13-7 6H-Thieno[2,3-c]pyridin-7-one 

Downstream Products

• 88255-40-7 7-(3,4-Dimethoxybenzyl)-thieno<2,3-c>pyridin 
• 104587-44-2 thieno<2,3-c>pyridine-7(6H)-thione 
• 87651-10-3 7-Allyl-6-methyl-6,7-dihydrothieno<2,3-c>pyridin 
• 104587-06-6 7-oxo-8-phenyl-7H-thieno<2,3-a>quinolizine-10-carboxylic acid 
• 104604-78-6 2-phenylthiazolo<3,2-a>thieno<2,3-c>pyridin-4-ium 3-oxide 
• 104587-49-7 methyl 7-oxo-8-phenyl-7H-thieno<2,3-a>quinolizine-10-carboxylate 
• 104586-97-2 N-(2-methoxyethyl)-7-oxo-8-phenyl-7H-thieno<2,3-a>quinolizine-10-carboxamide 
• 130888-44-7 10-<(morpholin-4-yl)carbonyl>-8-phenyl-7H-thieno<2,3-a>quinolizin-7-one 
• 104604-87-7 N-(3-methoxypropyl)-7-oxo-8-phenyl-7H-thieno<2,3-a>quinolizine-10-carboxamide 
• 104587-13-5 10-<(cis-2,6-dimethylmorpholin-4-yl)carbonyl>-8-phenyl-7H-thieno<2,3-a>quinolizin-7-one 
• 1078167-97-1 C₉H₇NO₂S 
• 1173825-66-5 C₁₅H₁₄N₂OS 
• 1402598-77-9 N-((7-chlorothieno[2,3-c]pyridin-2-yl)(phenyl)methyl)-3,4-dihydro-2H-1,5-benzodioxepine-7-sulfonamide 

Relevant articles and documents

BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

Design and synthesis of piperazinylpyridine derivatives as novel 5-HT 1A agonists/5-HT3 antagonists for the treatment of irritable bowel syndrome (IBS)

We have prepared a series of piperazinylpyridine derivatives for the treatment of irritable bowel syndrome (IBS). These compounds, which were designed by pharmacophore analysis, bind to both serotonin subtype 1A (5-HT 1A) and subtype 3 (5-HT3) receptors. The nitrogen atom of the isoquinoline, a methoxy group and piper-azine were essential to the pharmacophore for binding to these receptors. We also synthesized furo- and thienopyridine derivatives according to structure-activity relationship analyses. Compound 17c (TZB-20810) had high affinities to these receptors and exhibited 5-HT1A agonistic activity and 5-HT3 antagonistic activity concurrently, and is a promising drug for further development in the treatment of IBS.

Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

78. Tricyclic pyridine derivatives with high affinity to the central benzodiazepine receptor

Novel tricyclic heterocycles were prepared and evaluated for their affinity to the central benzodiazepine receptor. The most potent compounds with IC50's in the nanomolar range were found among thienoquinolizines and benzo[a]quinolizines (cf. Tables 2-5). The central ring of the tricyclic ring system may be partially unsaturated (cf. Tables 2 and 4) or fully unsaturated (cf. Tables 3 and 5) without loss of the high affinity to the receptor. The position of the ester group in the pyridinone ring is crucial for good binding (cf. Tables 1 and 2). It may be replaced by a broad variety of functional groups, e.g., amides, alkyl carbamates, alkyl groups, and hydroxyalkyl groups (cf. Tables 2-5). In the benzo[a]quinolizines, shifting the halogen atom from C(10) to C(9) leads to complete loss of affinity to the benzodiazepine receptor (cf. Table 4).

The Thienopyridine and Furopyridine Rings: New Pharmacophores with Potential Antipsychotic Activity

Two new arylpiperazine derivatives, the 4-(1-piperazinyl)thieno- and -furopyridine ring systems, have been synthesized and appended via tetramethylene chains to various imide rings.Target compounds from each series were found to have significant activity in the blockade of apomorphine stereotypy and apomorphine-induced climbing, the Sidman avoidance response, and the conditioned avoidance response.In addition, while potent affinity for serotonin 5-HT1 and 5-HT2 receptors was observed for both the thieno- and furopyridine derivatives,the interaction of these molecules with the dopamine D2 receptor was weak.Electrophysiological studies of the lead prototypes from each series, involving compounds 22 and 33, indicate these two molecules have distinctively different effects on dopamine neurons in areas A9 and A10.Despite the similarity these molecules share in their behavioral indices of antipsychotic acivity, it is likely that the thieno- and furopyridine rings employ different mechanisms to achieve this convergence of biological effects.

Tricyclic pyridine derivatives and pharmaceutical compositions

Compounds of the formula STR1 or a pharmaceutically acceptable acid addition salt of a compound of formula I which has one or more basic substituents, are described. The compounds of formula I possess pronounced muscle relaxant, sedative-hypnotic, anticonvulsive and anxiolytic properties and have low toxicity.